NCT05313802View on ClinicalTrials.gov

A Study of LY3502970 in Healthy Overweight and Obese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 26, 2022

Primary Completion Date

September 9, 2022

Study Completion Date

September 9, 2022

Conditions
HealthyObese
Interventions
DRUG

LY3502970

Administered orally.

Trial Locations (3)

33143

Qps-Mra, Llc, Miami

66219

ICON Early Phase Services Lenexa Center, Lenexa

78209

ICON Early Phase Services, San Antonio

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY